518048-02-7 Usage
Description
BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE is a complex organic compound characterized by its off-white solid appearance. It is primarily recognized for its role as an intermediate in the preparation of HIV-integrase inhibitors, which are crucial in the development of treatments for HIV/AIDS.
Uses
Used in Pharmaceutical Industry:
BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE is used as an intermediate in the synthesis of HIV-integrase inhibitors for the development of antiretroviral drugs. These inhibitors play a vital role in suppressing the replication of the HIV virus, thereby helping to manage and treat HIV/AIDS.
Used in Research and Development:
In the field of research and development, BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE serves as a valuable compound for exploring new avenues in the fight against HIV. Its unique chemical structure allows researchers to investigate its potential in creating novel therapeutic strategies and understanding the underlying mechanisms of HIV-integrase inhibition.
Used in Chemical Synthesis:
BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE is also utilized in various chemical synthesis processes, where its specific functional groups and structural features can be exploited to create a range of derivative compounds with potential applications in different industries, including pharmaceuticals, materials science, and agrochemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 518048-02-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,8,0,4 and 8 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 518048-02:
(8*5)+(7*1)+(6*8)+(5*0)+(4*4)+(3*8)+(2*0)+(1*2)=137
137 % 10 = 7
So 518048-02-7 is a valid CAS Registry Number.
InChI:InChI=1/C24H25FN4O5/c1-24(2,28-23(33)34-14-16-7-5-4-6-8-16)22-27-18(19(30)21(32)29(22)3)20(31)26-13-15-9-11-17(25)12-10-15/h4-12,30H,13-14H2,1-3H3,(H,26,31)(H,28,33)
518048-02-7Relevant articles and documents
(Chloromethyl)dimethylchlorosilane-KF: A Two-Step Solution to the Selectivity Problem in the Methylation of a Pyrimidone Intermediate en Route to Raltegravir
Stathakis, Christos I.,Gkizis, Petros L.,Alexandraki, Elli S.,Trakossas, Sakellarios,Terzidis, Michael,Neokosmidis, Efstratios,Zacharis, Constantinos K.,Vasiliadou, Christina,Vastardi, Elli,Andreou, Thanos,Zitrou, Asteria,Varvogli, Anastasia-Aikaterini,Koftis, Theocharis V.
, p. 1413 - 1418 (2017)
The present work describes a two-step process, namely, silylation with (chloromethyl)dimethylchlorosilane and desilylation, to address the selectivity problem in the N-methylation of a pyrimidone intermediate toward the synthesis of the raltegravir active pharmaceutical ingredient. The said methodology delivers the desired drug substance in which the O-methylated impurity content is below the detection limit by high-performance liquid chromatography analysis. Moreover, this two-step, one-pot procedure provides an apparent advantage in terms of environmental impact with respect to the optimum approach described in the literature, while it compares equally well in terms of cost and operational simplicity.
PROCESS FOR PREPARING COMPOUNDS USEFUL AS INTERMEDIATES FOR THE PREPARATION OF RALTEGRAVIR
-
Page/Page column 23-24, (2018/04/11)
The invention discloses a novel and selective methylation process used in the preparation of Raltegravir and intermediates. Further disclosed is an improved method for the reaction of intermediate amine compound of formula IIb with oxadiazole intermediate compound of formula V.
PROCESSES FOR PREPARING RALTEGRAVIR AND INTERMEDIATES IN THE PROCESSES
-
Page/Page column 17, (2012/08/08)
The present invention provides a process for preparing benzyl-2-(4-(4- fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2- ylcarbamate (RLT-8), a process for preparing Raltegravir via RLT-8, a process for preparing methyl 2-(2-(benzyloxycarbonylamino)propan-2-yl)-5 -hydroxy-1-methyl-6- oxo-1,6-dihydropyrimidine-4-carboxylate (RLT-7'), a process for preparing Raltegravir via RLT-7', and a process for preparing crystalline form V of Raltegravir potassium.